共查询到20条相似文献，搜索用时 52 毫秒
1.
中华医学会心血管病学分会心力衰竭学组 中华心力衰竭和心肌病杂志编辑委员会 中国医师协会心力衰竭专业委员会 国家心血管病专家委员会心力衰竭专业委员会 《中华心力衰竭和心肌病杂志(中英文)》2020,(1):8-15
新型冠状病毒肺炎(COVID-19)防控时期,心力衰竭(心衰)患者的诊治、随访和管理也体现了一定的特殊性.心衰患者合并新型冠状病毒感染后,可引起诊断评估上混淆,病情上互为加重,救治的复杂性和难度增加.本管理建议内容主要包括COVID-19防控时期对慢性和急性心衰的评估,药物和非药物的治疗,心衰常见合并症处理,COVID... 相似文献
2.
张宇辉;张萍;张抒扬;张健;王茜 《中华心力衰竭和心肌病杂志(中英文)》2020,4(01):8-15
新型冠状病毒肺炎（COVID-19）防控时期,心力衰竭（心衰）患者的诊治、随访和管理也体现了一定的特殊性。心衰患者合并新型冠状病毒感染后,可引起诊断评估上混淆,病情上互为加重,救治的复杂性和难度增加。本管理建议内容主要包括COVID-19防控时期对慢性和急性心衰的评估,药物和非药物的治疗,心衰常见合并症处理,COVID-19相关治疗药物的潜在心血管副作用,心衰患者的自我管理,以及特殊时期的随访等。 相似文献
3.
定点医院作为新型冠状病毒肺炎(COVID-19)相关病例的集中收治场所,是落实疫情防控工作的重要环节;营养治疗是临床综合治疗的核心内容之一,在改善COVID-19患者的营养状态、提高康复率、降低病死率等方面具有关键作用。为规范定点医院临床营养诊疗工作有序开展,保障临床营养诊疗工作的医疗安全和质量,上海市临床营养质量控制中心组织专家根据国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第九版)》,结合临床营养相关指南和诊疗经验编写了此建议,有助于在疫情防控期间,指导各医疗机构合理、有效开展COVID-19患者的营养诊疗工作。本指导意见重点针对成人及儿童COVID-19患者的营养管理建议进行阐述,为临床营养诊疗工作的开展提供参考。 相似文献
6.
新型冠状病毒肺炎(COVID-19)疫情以来,疾病的高传染性使确诊人数剧增,同时死亡人数也在日益增加。现全球已有200余个国家或地区出现感染病例。疾病的早诊可以有效控制疾病传播,同时使感染者得到有效的隔离和救治,提高生存率。目前,中国COVID-19的控制取得了阶段性胜利。本文对COVID-19的临床表现、实验室检查、... 相似文献
7.
新型冠状病毒肺炎(COVID-19)疫情以来,疾病的高传染性使确诊人数剧增,同时死亡人数也在日益增加。现全球已有200余个国家或地区出现感染病例。疾病的早诊可以有效控制疾病传播,同时使感染者得到有效的隔离和救治,提高生存率。目前,中国COVID-19的控制取得了阶段性胜利。本文对COVID-19的临床表现、实验室检查、影像学特征、分子学和血清学确诊方法及中国COVID-19诊疗方案多个修订版本诊断标准的变化进行综述,以期提高人们对该病的认识,为未来的研究提供更多的支持。 相似文献
8.
9.
10.
骨质疏松是一种与增龄相关的骨骼疾病,其严重后果是骨折,致死和致残率都高,需早期防治和有效合理地管理.2019年12月底我国从湖北省武汉市开始爆发了新型冠状病毒肺炎(COVID-19),目前研究表明老年和有慢性基础疾病的患者预后较差,也是主要的死亡人群.因此,疫情期间做好老年骨质疏松患者的科学防控和管理至关重要.为此本文... 相似文献
11.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(6):102319
Background and aimsThe current study was done to examine the efficacy of naproxen in the management of patients with COVID-19 infection.MethodsThis randomized, double-blind, placebo-controlled, clinical trial was done on hospitalized adult patients with confirmed COVID-19 infection. Patients were randomly assigned to receive either naproxen (two capsules per day each containing 500 mg naproxen sodium) or placebo (containing starch) for five days along with the routine treatment that was nationally recommended for COVID-19 infection. Clinical symptoms of COVID-19 infection, the time to clinical improvement, blood pressure, laboratory parameters, and death due to COVID-19 infection were considered as the outcome variables in the present study.ResultsTreatment with naproxen improved cough and shortness of breath in COVID-19 patients; such that, compared with placebo, naproxen intake was associated with 2.90 (95% CI: 1.10–7.66) and 2.82 (95% CI: 1.05–7.55) times more improvement in cough and shortness of breath, respectively. In addition, naproxen administration resulted in a significant increase in mean corpuscular volume (MCV) and had a preventive effect on the reduction of systolic blood pressure in COVID-19 patients.ConclusionTreatment with naproxen can improve cough and shortness of breath in COVID-19-infected patients. Further studies are required to confirm our findings. 相似文献
12.
13.
14.
15.
16.
《Annales de cardiologie et d'angeiologie》2020,69(3):107-114
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection. 相似文献
17.
18.
《The Indian journal of tuberculosis》2022,69(4):608-612
BackgroundThe ongoing coronavirus disease 2019 (COVID-19) calls for setting up of well-equipped and dedicated health facilities to manage sick patients while protecting healthcare workers and the environment. An ideal high-level isolation unit requires a high level of administrative commitment, availability of space, human resource and logistics.MethodThe experience of setting up COVID-19 care facilities on a noticeably short period in a tertiary TB and respiratory diseases institute in wake of the COVID-19 pandemic is being shared here.ResultAll the essential COVID-19 services were set up in record time of 8 days. A total of 115 COVID-19 patients were admitted. Out of these 89 patients were discharged in a satisfactory condition. There were 19 deaths, and 4 patients became critical and had to be referred to level 3 facility for ICU care.ConclusionThis experience will help other hospitals in planning out the strategies and solve the difficulties they may face while opening a COVID-19 care facility under limited resources on an urgent basis. 相似文献
19.
《Respiratory investigation》2021,59(5):666-669
An online questionnaire survey was used to assess the application of noninvasive strategies in the management of COVID-19 patients. We found a marked increase in the proportion of facilities using high flow nasal cannula (HFNC) oxygen therapy successfully in the 3rd epidemic wave as compared to the 1st wave (49% vs. 12%) and rare reports of associated nosocomial infection in the medical personnel. Furthermore, the proportion of facilities using HFNC as first-line therapy for half or more than half of their patients who did not respond to conventional oxygen therapy increased from 9% in the first to 33% in the second survey. Conversely, the rate of mechanical ventilation with intubation usage following conventional oxygen therapy failure decreased from 62% to 54%. These changes could be due to the limited medical resources available during the larger 3rd wave coupled with increased internal reports on the success of HFNC. 相似文献
20.
BackgroundAs COVID-19 vaccine effectiveness against SARS-CoV-2 infection was lower for cases of the Omicron vs the Delta variant, understanding the effect of vaccination in reducing risk of hospitalisation and severe disease among COVID-19 cases is crucial.AimTo evaluate risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the Omicron BA.1-predominant period in Navarre, Spain.MethodsA case-to-case comparison included COVID-19 epidemiological surveillance data in adults ≥ 18 years from 3 January–20 March 2022. COVID-19 vaccination status was compared between hospitalised and non-hospitalised cases, and between severe (intensive care unit admission or death) and non-severe cases using logistic regression models.ResultsAmong 58,952 COVID-19 cases, 565 (1.0%) were hospitalised and 156 (0.3%) were severe. The risk of hospitalisation was reduced within the first 6 months after full COVID-19 vaccination (complete primary series) (adjusted odds ratio (aOR): 0.06; 95% CI: 0.04–0.09) and after 6 months (aOR: 0.16; 95% CI: 0.12–0.21; pcomparison < 0.001), as well as after a booster dose (aOR: 0.06: 95% CI: 0.04–0.07). Similarly, the risk of severe disease was reduced (aOR: 0.13, 0.18, and 0.06, respectively). Compared with cases fully vaccinated 6 months or more before a positive test, those who had received a booster dose had lower risk of hospitalisation (aOR: 0.38; 95% CI: 0.28–0.52) and severe disease (aOR: 0.38; 95% CI: 0.21–0.68).ConclusionsFull COVID-19 vaccination greatly reduced the risk of hospitalisation and severe outcomes in COVID-19 cases with the Omicron variant, and a booster dose improved this effect in people aged over 65 years. 相似文献
